

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Filgotinib for treating moderately to severely active ulcerative colitis

Batch 74

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

The mode of administration (oral) is a benefit for those with disabilities in terms of reducing the need to travel to hospital, potentially improving adherence. This may also be a factor in cultures where it may be harder to speak openly about the condition or for those living in remote communities.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

This does not need to be considered by committee as it does not relate to a barrier to access for filgotinib specifically. However, the committee will consider whether the innovative nature of the technology (including its oral administration) adds demonstrable and distinctive benefits of a substantial nature which may not have been adequately captured in the reference case QALY measure.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes were made to the draft scope to highlight any potential equality issues.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix

been made?

No additional stakeholders related to potential equality issues were identified during the scoping process.

Approved by Associate Director (name): Henry Edwards

Date: 12/02/2021